Flare Therapeutics, a clinical-stage biotechnology company, has successfully closed an $85 million Series C financing round led by its existing investors. Concurrent with the funding, the company announced the appointment of veteran biotech executive Anna Protopapas as its new Chief Executive Officer. This capital infusion and leadership change will fuel the company's strategic focus on advancing its novel treatments for prostate cancer.
Strategic Financing to Advance Oncology Pipeline
The financing was spearheaded by Third Rock Ventures and Nextech Invest, with significant participation from Pfizer Ventures, Eli Lilly and Company, and Novartis, among others. Proceeds are earmarked to advance the company’s lead candidate, FX-111, and its preclinical ARON RIPTAC program. This substantial investment highlights strong investor confidence in FlareTx's innovative approach to targeting transcription factors in oncology.
Following a strategic review, FlareTx will concentrate its resources on FX-111, a first-in-class degrader targeting the androgen receptor in prostate cancer. This molecule is designed to overcome key resistance mechanisms that limit the efficacy of conventional hormone-based therapies. The company's focused strategy aims to address high-risk, AR-driven disease across all its stages.
Clinical and Preclinical Program Momentum
The company has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration for FX-111. FlareTx expects to initiate a Phase 1A clinical study for the candidate in the third quarter of 2026. This milestone marks a critical transition from preclinical research to human trials for its lead asset.
Complementing its lead program, FlareTx is also advancing an ARON RIPTAC (Regulated Induced Proximity Targeting Chimeras) program through preclinical development. This dual approach expands the company's ability to address the full continuum of prostate cancer. Meanwhile, FlareTx intends to seek an external partnership to further develop its urothelial cancer candidate, FX-909.
New Leadership to Guide Next Growth Phase
Anna Protopapas will take the helm as Chief Executive Officer, bringing extensive experience in oncology development and commercialization. She most recently served as President and CEO of Mersana Therapeutics, where she guided the company's transition to a public entity. Her appointment is timed to lead FlareTx through its next critical phase of clinical growth.
Ms. Protopapas's distinguished career includes leadership roles as President of Millennium, a Takeda subsidiary, and Executive Vice President of Global Business Development at Takeda. Her track record includes steering acquisitions and partnerships that catalyzed significant corporate growth and globalization. She has also served on the boards of several successful biotech firms, including Nuvalent and ARIAD Pharmaceuticals.
Investor Confidence in Differentiated Approach
Investors have expressed strong conviction in the company's scientific direction and its potential to impact patients. Kanishka Pothula of Nextech Invest noted that FlareTx’s ARON-targeting approach is highly differentiated and could address major limitations of current prostate cancer therapies. This financing reflects continued belief in the team and its platform.
Abbie Celniker of Third Rock Ventures echoed this sentiment, citing the company's differentiated transcription factor platform as a key reason for continued support. The firm praised the team for advancing novel programs into the clinic with potentially transformational impact. They also warmly welcomed Ms. Protopapas, highlighting her proven leadership as an exceptional fit for the company.
With the successful closure of its $85 million Series C financing and the strategic appointment of Anna Protopapas, Flare Therapeutics is strongly positioned for its next chapter. The company is now well-capitalized and equipped with experienced leadership to advance its lead candidate, FX-111, into clinical trials. This focused effort holds significant promise for developing new, more effective treatments for patients with prostate cancer.